Despite the use of low-molecular-weight heparins, venous thromboembolism remains prevalent in major orthopaedic surgery, necessitating new prevention strategies.
Answers are grounded in this paper and cite their sources.
Ongoing VTE risk despite LMWH in orthopaedic surgery warrants clinical vigilance; leaves open need for novel prophylaxis trials.
Venous thromboembolism remains a major cause of morbidity and mortality among patients undergoing major orthopaedic surgery. With improved surgical techniques, the use of heparin-based thromboprophylactic agents has allowed significant advances in the prevention of thrombosis during the past 30 years. With an aging population and the growing burden of degenerative joint disease, the management of this preventable disease remains at the forefront of surgical care. Despite the use of the supposedly most effective antithrombotic agents (low-molecular-weight heparins), recent studies have highlighted considerable prevalence of thrombosis, especially among hip fracture patients. New prevention strategies include a greater use of existing therapies, combining chemical and mechanical methods, extending the duration of prophylaxis and, most importantly, developing more effective agents with improved benefit to risk ratios.
No takes yet. Share an insight, caveat, or question.
McCahill et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: